Stock OCGN OCUGEN, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Ocugen, Inc.

Equities

OCGN

US67577C1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-16 pm EDT 		After market 07:08:31 pm
1.98 USD +1.02% Intraday chart for Ocugen, Inc. 1.975 -0.25%
May. 15 Ocugen Completes Dosing of Second Group in Stargardt Eye Therapy Safety and Efficacy Study MT
May. 15 Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST?A Modifier Gene Therapy CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy
GL
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
PR
ROSEN, A LEADING LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
NE
Ocugen Provides Business Update with First Quarter 2024 Financial Results
GL
Ocugen: Q1 Earnings Snapshot
AQ
OCUGEN TO PRESENT AT MAY 2024 INVESTOR CONFERENCES
AQ
OCUGEN ANNOUNCES DISTRIBUTION OF SERIES C PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK
AQ
ROSEN, A TOP RANKED LAW FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
Ocugen Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
GL
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
PR
Ocugen to Present at May 2024 Investor Conferences
GL
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
NE
OCUGEN TO HOST CONFERENCE CALL ON TUESDAY, MAY 14 AT 8:30 A.M. ET TO DISCUSS BUSINESS UPDATES AND FIRST QUARTER 2024 FINANCIAL RESULTS
AQ
ROSEN, THE FIRST FILING FIRM, Encourages Ocugen, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - OCGN
PR
Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ocugen
PR
Ocugen to Host Conference Call on Tuesday, May 14 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2024 Financial Results
GL
Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
GL
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Ocugen, Inc. with Losses to Contact the Firm
PR
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ocugen, Inc. (OCGN) on Behalf of Investors
BU
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. OCGN Stock
  4. News Ocugen, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW